Karolinska Development
1.57 SEK -0.13%1 investor is following this company
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Revenue
2.01M
EBIT %
-174.63 %
P/E
78.5
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
KDEV
Daily low / high price
1.55 / 1.586
SEK
Market cap
424.02M SEK
Turnover
33.57K SEK
Volume
21K
Financial calendar
General meeting
2024-05-16
Interim report
2024-08-30
Interim report
2024-11-15
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
invoX Pharma Ltd | 47.7 % | 43.9 % |
Worldwide International Investments Ltd | 10.4 % | 9.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Interim Report - January-March 2024
Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools